Premium
Association of anti‐ RNA polymerase III antibody and malignancy in Japanese patients with systemic sclerosis
Author(s) -
Saigusa Ryosuke,
Asano Yoshihide,
Nakamura Kouki,
Miura Shunsuke,
Ichimura Yohei,
Takahashi Takehiro,
Toyama Tetsuo,
Taniguchi Takashi,
Noda Shinji,
Aozasa Naohiko,
Akamata Kaname,
Sumida Hayakazu,
Miyazaki Miki,
Tamaki Zenshiro,
Yanaba Koichi,
Kuwano Yoshihiro,
Sato Shinichi
Publication year - 2015
Publication title -
the journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.9
H-Index - 65
eISSN - 1346-8138
pISSN - 0385-2407
DOI - 10.1111/1346-8138.12827
Subject(s) - malignancy , autoantibody , antibody , medicine , immunology , population , environmental health
Patients with systemic sclerosis ( SS c) have an increased risk of malignancy compared with the general population. Recently, SS c patients with anti‐ RNA polymerase III antibody have been reported to have an increased risk of malignancy as compared with those with other disease‐specific autoantibodies in US, European and Australian populations. Therefore, we studied the relationship between disease‐specific autoantibodies and malignancy in 261 Japanese SS c patients. The prevalence of malignancy was significantly higher in patients with anti‐ RNA polymerase III antibody (7/22, 31.8%) than in those with anti‐topoisomerase I antibody (2/82, 2.4%) and in those with anticentromere antibody (8/137, 5.8%). Importantly, among seven patients with anti‐ RNA polymerase III antibody and malignancy, three patients (42.9%) developed malignancy from 6 months before to 12 months after SS c onset. Thus, malignancy complication in Japanese SS c patients with anti‐ RNA polymerase III antibody is as high as that in other races, suggesting that SS c patients with anti‐ RNA polymerase III antibody share the same pathological process among different ethnic groups.